SCHEMBL3661430

SCHEMBL3661430

O=c1[nH]cnc2ccc(S(=O)(=O)O)cc12

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.61
CHEK1 O14757 1/20 0.57
PIM1 P11309 1/20 0.57
AKT1 P31749 1/20 0.57
FLT3 P36888 1/20 0.57
PIM3 Q86V86 1/20 0.57
SLC2A1 P11166 1/20 0.55
IP6K1 Q92551 9/20 0.53
IP6K3 Q96PC2 6/20 0.52
PDPK1 O15530 1/20 0.50
CA12 O43570 1/20 0.50
ALOX15 P16050 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CA9 Q16790 1/20 0.50
TNKS2 Q9H2K2 1/20 0.50
IP6K2 Q9UHH9 3/20 0.49
ACVR1 Q04771 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11219601 0.98 PARP1 (0.59) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL858781 0.84 PARP1 (0.61) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL3659063 0.84 PARP1 (0.61) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL7174501 0.84 PARP1 (0.61) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL571364 0.80 PRKCI (0.52) SMN1; SMN2
SCHEMBL29724218 0.80 PRKCI (0.52) SMN1; SMN2
Hydrochloric Acid SCHEMBL11090118 0.78 KDM4E (0.53) SMN1; SMN2
Potassium SCHEMBL2918771 0.78 PRKCI (0.50) SMN1; SMN2
SCHEMBL642178 0.76 PARP1 (1.00) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL8622180 0.75 ACVR1 (0.73) PARP1CHEK1PIM1AKT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2011-03-17 US disclosed
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2011-03-17 US disclosed
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2011-03-17 US disclosed
EP-2220042-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2010-08-25 EP disclosed
WO-2009063054-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2009-05-22 WO disclosed
WO-2009063054-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2009-05-22 WO disclosed
EP-2060565-A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases 4SC AG (DE) 2009-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES HDAC1, HDAC11, MAP2K2 PARP1 461/4885CHEK1 169/4885PIM1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.